ACYP2

Across TCGA pan-cancer cohorts, ACYP2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ACYP2 data layer compared with 28 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ACYP2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ACYP2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

UCEC, PDAC, and LUAD are the cancer types where ACYP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	III,IV	0.274	1.000	.002	32	view →
PDAC	DFS	Median	IV	0.785	0.214	.006	13	view →
LUAD	DFS	Quartile	III,IV	0.511	0.901	.009	7	view →
HNSC	DFS	Quartile	II,III,IV	0.892	1.000	.015	3	view →
GBM	DFS	Median	All	0.251	0.485	.011	2	view →
CCRCC	DFS	Median	All	0.839	0.659	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ACYP2–UCEC (DFS)

Open the UCEC breakdown →